

Covid-19 and Influenza Oral Vaccine Study

NCT06355232

Status	RECRUITING
Phase	Phase 1
Sponsor	Vaxine Pty Ltd
Enrollment	100 participants

Key Eligibility Criteria

Inclusion (4)

- Able to provide written informed consent
- Males or females 18 years of age or older
- Understand and are likely to comply with planned study procedures and be available for all study visits.
- Do not plan to have a non-study COVID-19 or influenza vaccine within the next 6 months.

Exclusion (3)

- Allergy to COVID-19 or seasonal influenza vaccine or one of its components e.g. polysorbate 80.
- Have received a COVID-19 or influenza vaccine or an experimental agent within 30 days prior to the study vaccination or expect to receive another experimental agent or a COVID-19 or influenza vaccine during the trial reporting period.
- Any serious medical, social or mental condition which, in the opinion of the investigator, would be detrimental to the subjects or the study.

Locations (1 total)

ARASMI, Adelaide, South Australia, Australia